Danish drugmaker reaches settlement with United States authorities

Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Novo Nordisk A/S (NYSE:NVO). More interesting news about Novo Nordisk A S (ADR) (NYSE:NVO) were released by: Fool.com and their article: “Why Novo Nordisk A/S Got Crushed Today” published on October 28, 2016 as well as Seekingalpha.com’s news article titled: “Portfolio Update – Novo Nordisk Purchased” with publication date: November 22, 2016. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the period.

Boston Advisors Llc increased Validus Holdings Ltd Com Shs (NYSE:VR) stake by 7,248 shares to 111,666 valued at $6.14M in 2016Q4. Parallel Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock valued at $117,000 after acquiring an additional 1,553 shares in the last quarter. Finally, Wayne Hummer Investments L.L.C. bought a new stake in Novo Nordisk A/S in the 1st quarter valued at $209,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in Novo Nordisk A/S by 3,609.0% during the first quarter. The fund owned 26,682 shares of the company’s stock after selling 1,101 shares during the quarter. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of United States and global copyright legislation. If you are reading this story on another site, it was illegally copied and republished in violation of USA & worldwide trademark and copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2017/09/07/novo-nordisk-as-nvo-position-raised-by-alphamark-advisors-llc.html. Bank of America downgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Friday, October 28 to “Underperform” rating. BidaskClub downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. Northwestern Mutual Wealth Mngmt Company holds 0% in Rowan Companies PLC (NYSE:RDC) or 55 shares. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has “Equal-Weight” rating given on Thursday, September 1 by Morgan Stanley.

More notable recent Biogen Inc (NASDAQ:BIIB) news were published by: Investorplace.com which released: “Trade of the Day: Biogen Inc (BIIB) Stock Is Coiling” on August 29, 2017, also Nasdaq.com with their article: “Steven Cohen Buys Biogen Inc, Alphabet Inc, Comcast Corp, Sells Facebook Inc …” published on August 15, 2017, Benzinga.com published: “Why It’s Useful To Know A Company’s Competitors When Trading” on September 05, 2017. The stock has a market cap of $119.90 billion, a PE ratio of 19.9354 and a beta of 0.60.

It is trading at $47.84 slightly over the 50 day moving average which is $44.39 and much higher than the 200 day moving average of $40.27. With short interest at 2,810,963 and short average daily volume at 1,672,150, the short-interest ratio is 2.0 and the percentage of shorted shares was 0.00% on August 15. The stock has “Market Perform” rating by Leerink Swann on Friday, August 28. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. This represents a yield of 1.07%. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since September 7, 2016 and is downtrending.

This portion of the settlement resolves allegations that Novo Nordisk caused the submission of false claims from 2010 to 2014 to federal health care programs for Victoza by arming its sales force with messages that could create a false or misleading impression with physicians that the Victoza REMS-required message about the potential risk of MTC associated with Victoza was erroneous, irrelevant, or unimportant and by encouraging the sale to and use of Victoza by adult patients who did not have Type II diabetes. The Firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Firm operates through two business divisions: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Leave a Reply

Your email address will not be published. Required fields are marked *